Sevcad 100 Mg. Sevcad 150 Mg 100 mg. 150 mg Soft gelatin capsules
PDF Leaflet Revision Date: 27 January 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of Idiopathic Pulmonary Fibrosis and other chronic fibrosing ILDs.
Dosage (summary)
150 mg every 12 hours; 100 mg if 150 mg is not tolerated.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; use effective contraception. Breastfeeding should be discontinued.
Key Drug Interactions
- P-glycoprotein inhibitors
- P-glycoprotein inducers
Contraindications
- Hypersensitivity to nintedanib or soya
- Pregnancy
Common side effects
- Diarrhoea
- Nausea
- Vomiting
- Increased hepatic enzymes
Counselling Points
- Take with food
- Monitor for gastrointestinal symptoms
- Avoid pregnancy during treatment
Serious warnings
- Risk of gastrointestinal perforation
- Increased risk of bleeding
- Liver injury
Important Disclaimer
The Sevcad 100 Mg. Sevcad 150 Mg 100 mg. 150 mg Soft gelatin capsules professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
